Track topics on Twitter Track topics that are important to you
As more and more patients with rheumatic disease switch from a biologic to a biosimilar, a new study assesses how many switch back to the originator.
Medscape Medical News
Original Article: One in 10 in Rheumatic Pain Switch Back From a BiosimilarNEXT ARTICLE
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...